Drug Profile
IPI 493
Alternative Names: 17-AG; 17-Aminogeldanamycin; IPI-493; NSC-255109Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Infinity Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Haematological malignancies; Solid tumours
Most Recent Events
- 16 Nov 2011 Adverse events & pharmacokinetics data from 2 phase I trials in Solid tumours & Haematological malignancies presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- 10 Jun 2011 Discontinued - Phase-I for Haematological malignancies in USA (PO)
- 10 Jun 2011 Discontinued - Phase-I for Solid tumours in USA (PO)